We Can Medicines Co., Ltd. (6929) Stock Statistics & Valuation Metrics
Total Valuation
We Can Medicines Co., Ltd. has a market cap or net worth of TWD 899.55M. The enterprise value is TWD 1.96B.
- Market Cap
- TWD 899.55M
- Enterprise Value
- TWD 1.96B
Share Statistics
We Can Medicines Co., Ltd. has 45,090,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,090,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
We Can Medicines Co., Ltd.’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -2.97%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -2.97%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 3.16M
- Profits Per Employee
- -71.78K
- Employee Count
- 1,020
- Asset Turnover
- 1.08
- Inventory Turnover
- 2.93
Valuation Ratios
The current PE Ratio of We Can Medicines Co., Ltd. is -12.43. We Can Medicines Co., Ltd.’s PEG ratio is 1.81.
- PE Ratio
- -12.43
- PS Ratio
- 0.30
- PB Ratio
- 0.96
- Price to FCF
- 3.73
- Price to Operating Cash Flow
- 3.27
- PEG Ratio
- 1.81
Income Statement
In the last 12 months, We Can Medicines Co., Ltd. had revenue of 3.22B and earned -73.21M in profits. Earnings per share was -1.63.
- Revenue
- 3.22B
- Gross Profit
- 747.34M
- Operating Income
- -68.02M
- Pretax Income
- -73.19M
- Net Income
- -73.21M
- EBITDA
- 252.68M
- Earnings Per Share (EPS)
- -1.63
Cash Flow
In the last 12 months, operating cash flow was 296.91M and capital expenditures -37.33M, giving a free cash flow of 259.58M billion.
- Operating Cash Flow
- 296.91M
- Free Cash Flow
- 259.58M
- Free Cash Flow per Share
- 5.76
Dividends & Yields
We Can Medicines Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 27.74%
- Earnings Yield
- -8.34%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- -27.19%
- 50-Day Moving Average
- 21.84
- 200-Day Moving Average
- 25.48
- Relative Strength Index (RSI)
- 34.09
- Average Volume (3m)
- 7,420
Important Dates
We Can Medicines Co., Ltd. upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
We Can Medicines Co., Ltd. as a current ratio of 1.53, with Debt / Equity ratio of 114.23%
- Current Ratio
- 1.53
- Quick Ratio
- 0.64
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 3.77
- Interest Coverage Ratio
- -2.66
Taxes
In the past 12 months, We Can Medicines Co., Ltd. has paid 18.00K in taxes.
- Income Tax
- 18.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
We Can Medicines Co., Ltd. EV to EBITDA ratio is 7.38, with an EV/FCF ratio of 7.02.
- EV to Sales
- 0.57
- EV to EBITDA
- 7.38
- EV to Free Cash Flow
- 7.02
- EV to Operating Cash Flow
- 6.14
Balance Sheet
We Can Medicines Co., Ltd. has TWD 223.72M in cash and marketable securities with TWD 1.11B in debt, giving a net cash position of -TWD 887.69M billion.
- Cash & Marketable Securities
- TWD 223.72M
- Total Debt
- TWD 1.11B
- Net Cash
- -TWD 887.69M
- Net Cash Per Share
- -TWD 19.69
- Tangible Book Value Per Share
- TWD 22.28
Margins
Gross margin is 22.86%, with operating margin of -2.37%, and net profit margin of -2.43%.
- Gross Margin
- 22.86%
- Operating Margin
- -2.37%
- Pretax Margin
- -2.43%
- Net Profit Margin
- -2.43%
- EBITDA Margin
- 7.70%
- EBIT Margin
- -2.26%
Analyst Forecast
The average price target for We Can Medicines Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -1.09%
- EPS Growth Forecast
- -5.06%
